Unravelling the potential neuroprotective facets of erythropoietin for the treatment of Alzheimer's disease.

Autor: Kaur D; Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India., Behl T; Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India. tapanbehl31@gmail.com., Sehgal A; Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India., Singh S; Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India., Sharma N; Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India., Badavath VN; Chitkara College of Pharmacy, Chitkara University, Rajpura, Punjab, India., Ul Hassan SS; School of Medicine and Pharmaceutical Sciences, Zhejiang University, Hangzhou, China., Hasan MM; Department of Biochemistry and Molecular Biology, Faculty of Life Science, Mawlana Bhashani Science and Technology University, Tangail, Bangladesh., Bhatia S; Natural & Medical Sciences Research Centre, University of Nizwa, Nizwa, Oman.; Amity Institute of Pharmacy, Amity University, Noida, Haryana, India., Al-Harassi A; Natural & Medical Sciences Research Centre, University of Nizwa, Nizwa, Oman., Khan H; Department of Pharmacy, Abdul Wali Khan University Mardan, Mardan, Pakistan., Bungau S; Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, Oradea, Romania.
Jazyk: angličtina
Zdroj: Metabolic brain disease [Metab Brain Dis] 2022 Jan; Vol. 37 (1), pp. 1-16. Date of Electronic Publication: 2021 Aug 26.
DOI: 10.1007/s11011-021-00820-6
Abstrakt: During the last three decades, recombinant DNA technology has produced a wide range of hematopoietic and neurotrophic growth factors, including erythropoietin (EPO), which has emerged as a promising protein drug in the treatment of several diseases. Cumulative studies have recently indicated the neuroprotective role of EPO in preclinical models of acute and chronic neurodegenerative disorders, including Alzheimer's disease (AD). AD is one of the most prevalent neurodegenerative illnesses in the elderly, characterized by the accumulation of extracellular amyloid-ß (Aß) plaques and intracellular neurofibrillary tangles (NFTs), which serve as the disease's two hallmarks. Unfortunately, AD lacks a successful treatment strategy due to its multifaceted and complex pathology. Various clinical studies, both in vitro and in vivo, have been conducted to identify the various mechanisms by which erythropoietin exerts its neuroprotective effects. The results of clinical trials in patients with AD are also promising. Herein, it is summarized and reviews all such studies demonstrating erythropoietin's potential therapeutic benefits as a pleiotropic neuroprotective agent in the treatment of Alzheimer's disease.
(© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: